Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population

Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population

Donnie Funch,1 Kathleen Mortimer,1 Najat J Ziyadeh,1 John D Seeger,1 Li Zhou,1 Eva Ng,1 Douglas Ross,2,3 Atheline Major-Pedersen,4 Heidrun Bosch-Traberg,5 Helge Gydesen,6 David D Dore1,7 1Optum Epidemiology, Boston, MA, USA; 2Massachusetts General Hospital, Thyroid Associates, Boston, MA, USA; 3Harv...

Full description

Bibliographic Details
Main Authors: Funch D, Mortimer K, Ziyadeh NJ, Seeger JD, Zhou L, Ng E, Ross D, Major-Pedersen A, Bosch-Traberg H, Gydesen H, Dore DD
Format: Article
Language:English
Published: Dove Medical Press 2021-06-01
Series:Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Subjects:
glucagon-like peptide-1 receptor agonist
type 2 diabetes
administrative claims
intention-to-treat
time-on-drug
Online Access:https://www.dovepress.com/risk-of-thyroid-cancer-associated-with-use-of-liraglutide-and-other-an-peer-reviewed-fulltext-article-DMSO

Internet

https://www.dovepress.com/risk-of-thyroid-cancer-associated-with-use-of-liraglutide-and-other-an-peer-reviewed-fulltext-article-DMSO

Similar Items